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Roger D. Yusen, MD, MPH, and Josef Stehlik, MD, MPH; for the International Society for
Heart and Lung TransplantationFrom the The ISHLT Transplant Registry, Dallas, Texas.Pediatric heart transplantation has grown worldwide since
the first procedure in 1967. With more than 11,000 trans-
plants in children reported, the Registry of the International
Society for Heart and Lung Transplantation (ISHLT) is well
poised to examine the evolving management of pediatric
heart transplant recipients and their outcomes.Registry data sources and statistical methods
ISHLT Registry data are provided by individual centers and
national or regional Organ Procurement and Organ
Exchange Organizations; these are listed in the introduction
to the Annual Reports.
This 16th pediatric heart transplant report from the
ISHLT Registry is centered on age as the central theme,
focusing on the year 2000 onwards. Key topics include
geographic trends, diagnosis, survival, and the conventional
post-transplant morbidities. A number of these character-
istics and outcomes were analyzed for age-related differ-
ences between the newly defined age groups of 0 to o1
year, 1 to 5 years, 6 to 10 years, and 11 to 17 years. In
follow-up of last year’s reported regional variation, we
explored interactions among age, diagnosis, and geography
and their respective effect on transplant survival. The Tables
and Figures published in this report, as well as the slides
describing additional analyses, are available for downloadt matter Published by Elsevier Inc.
16/j.healun.2013.08.005
ef.stehlik@hsc.utah.edu
osef Stehlik, MD, MPH, University of Utah Health
ision of Cardiology, U.T.A.H. Cardiac Transplant
cal Dr, 4A100 SOM, Salt Lake City, UT 84132.
340. Fax: 801-581-7735.from www.ishlt.org/registries.1 Source data can be accessed
by clicking the graphs and selecting “edit data.” Data for the
previous 12 ISHLT Registry reports can also be accessed
through the ISHLT Web site.1,2
Survival rates were calculated using the Kaplan-Meier
method and compared using the log-rank test. Adjustments
for multiple comparisons were done using Scheffe’s
method. Multivariable analyses were performed using Cox
proportional hazard regression analysis. Results of the
multivariable analyses are reported as the hazard ratio
(HR) with a corresponding 95% confidence interval (CIs)
and/or p-value. Factors with a HR significantly4 1 indicate
that the factor is associated with an increased likelihood of
the event occurring. Conversely, a HR ofo 1 indicates that
the event is less likely to occur when that factor is present.
Multiple imputations were used to handle missing informa-
tion for continuous data fields, such as ischemia time and
donor age.3 This method produces an estimated value for the
missing value based on the other characteristics of the
patient, donor, and/or transplant. The algorithm is per-
formed multiple times, producing new estimates for the
missing information. Models are fit on each imputed data
set and then combined to produce a final set of estimates
from which the relative risk estimates and p-values are
obtained.Centers and activity
There were 565 heart transplants in children (aged o 18
years) reported to the Registry in 2011 (Figure 1), a slight
increase from previous years. These comprise 14% of all
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NOTE: This figure includes only the heart transplants that are reported to the ISHLT 
Transplant Registry.  As such, this should not be construed as evidence that the number
of hearts transplanted worldwide has increased and/or decreased in recent years. 
Figure 1 Recipient age distribution by year of transplant.
ISHLT, International Society for Heart and Lung Transplantation.
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Figure 2 Distribution of transplants by center volume
(Transplants: January 2000–June 2012).
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Figure 4 Distribution of transplants by location and average
center volume (Transplants: January 2000–June 2012).
Figure 5 Recipient diagnosis in recipients aged o 1 year.
ReTX, retransplant.
The Journal of Heart and Lung Transplantation, Vol 32, No 10, October 2013980cardiac transplants. The proportion of pediatric transplants
by recipient age has remained relatively stable for the last
decade. Of the centers reporting pediatric heart transplants
in 2011, 54 were from North America, 40 from Europe, and
12 from the other parts of the world, with the most notable
change being the slow increase over time in the number of
centers reporting to the Registry other than from Europe or
North America.1
For the most recent era, 53% of the transplants in the
Registry were undertaken in larger centers (Z 10 pediatric
heart transplants performed per year) compared with 40% in
2000 to 2005 (Figure 2). Between 2006 and June 2012, 25%
of all transplants were still performed in centers undertaking
o 4 transplants per year. These smaller centers were less
likely to transplant the younger groups of pediatric0%
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Figure 3 Age distribution by center volume (Transplants: January
2000–June 2012).recipients: between 2000 and 2012, 4 50% of transplants
were in the group aged 11 to 17 years, and only 14% were in
recipients aged o 1 year (Figure 3). Small but statistically
significant differences were noted in age distribution by
center volume for centers doing4 5 transplants per year. In
addition, there were significant geographic differences: only
25% of European centers undertook4 10 transplants a year
compared with 50% of North American centers and none of
the centers in other regions (Figure 4).Indications for transplantation
Congenital heart disease remains the most common
indication for heart transplant in the infant age group
(54%) but has significantly decreased over time, while
cardiomyopathy increased from 35% in the period 2000 to
2005 to 41% in the most recent era (Figure 5). For the otherEurope North America Other
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Figure 6 Diagnosis distribution by location (Transplants: January
2000–June 2012). Re-TX, retransplant.
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Figure 7 Recipient age distribution by location (Transplants:
January 2000-June 2012).
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Figure 9 Panel reactive antibody distribution by year (Trans-
plants: January 2005–December 2011).
Dipchand et al. ISHLT 16th Pediatric Heart Transplant Report 981age groups, the indications for pediatric heart transplantation
have remained remarkably stable over time: approximately
65% and 25% of the 11-to 17-year-olds and 55% and 38%
of the 1- to 10-year olds had a transplant for cardiomyop-
athy and congenital heart disease, respectively. There are
geographic differences, with congenital heart disease
remaining a more common indication in North America.Recipient characteristics
Approximately 25% of transplant recipients in 2011 were
infants (age o 1 year), 22% were aged between 1 and
5 years, 15% were between 6 and 10 years, and 40% were
between 11 and 17 years (Figure 1). Infants comprised 28%
of North American transplants compared with 12% in
Europe and 5% in the rest of the world, where the group
aged 11 to 17 years predominated (59%; Figure 7).
The proportion of children bridged to transplantation
with mechanical circulatory support (MCS) remained stable
at 26% in 2011, comprising a ventricular assist device
(VAD) or total artificial heart (TAH) in 20%, extracorporeal
membrane oxygenation (ECMO) in 4%, and ECMO and
VAD in 2%. Of infants bridged with MCS, ECMO was used
in 60%, a proportion that decreased with increasing age
down to 18% for the group aged 11 to 17 years (Figure 8).
The proportion of sensitized patients with a panel
reactive antibody (PRA) of Z 10% remained stable at
27% (Figure 9). Looking at age, the infant group had the21.0
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Figure 8 Percentage of patients bridged with mechanical
circulatory support by age group (Transplants: July 2004–June
2012). ECMO, extracorporeal membrane oxygenation; LVAD, left
ventricular assist device; RVAD, right ventricular assist device;
TAH, total artificial heart; VAD, ventricular assist device.lowest proportion of sensitized recipients (18%), with the
highest being age 1 to 5 years and 6 to 10 years, at 28% to
29% (Figure 10). Adult recipients were less likely to be
sensitized, with 19% having a PRA of 10% or more.4Donor characteristics
Twenty-five percent of pediatric recipients receive a heart
from an adult donor (4 18 years). Similarly to what was
reported last year, a significant geographic variation exists in
the proportion of adult donors allocated to pediatric
recipients: 18% in North America, 43% in Europe, and
48% in the rest of the world. Not surprisingly, the groups
aged 6 to 10 years and 11 to 17 years used the broadest
spectrum of donors by age (Figure 11). Sixty-eight percent
of recipients received a size-matched donor heart (weight
ratio, 1.0–1.9), and no substantial changes have occurred
during the last decade.Immunosuppression
Induction
As noted last year and still in contrast to the adult
population,3 the use of induction therapy continues to trend
upwards. Most pediatric heart transplant recipients (71%)
receive induction therapy, comprising 47% anti-thymocyte
globulin and 25% interleukin-2 receptor (IL2-R) antago-
nists. In a univariate analysis examining survival out to
9 years after transplant, patients who received polyclonal
induction therapy had a better survival than those who0%
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Figure 10 Panel reactive antibody distribution by age group
(Transplants: July 2004–June 2012).
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Figure 15 Kaplan-Meier survival by era (Transplants: January
1982–June 2011).
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Figure 12 Maintenance immunosuppression at time of trans-
plant discharge by age (Follow-up: January 2007–June 2012).
MMF, mycophenolate mofetil; MPA, mycophenolic acid.
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Su
rv
iv
al
 (%
)
Years
Median survival <1: 19.7 Years; 1-5: 16.8 Years; 6-10: 14.5 Years; 11-17: 12.4 Years
Figure 14 Kaplan-Meier survival for pediatric heart transplant
recipients (Transplants: January 1982–June 2011).
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Figure 11 Donor and recipient age (Transplants: January 2000–
June 2012).
The Journal of Heart and Lung Transplantation, Vol 32, No 10, October 2013982received IL2-R antagonists (p ¼ 0.014). In a number of sub-
group analyses, we were not able to identify patient
characteristics that would suggest survival benefit with the
use of induction. Specifically, there was no survival benefit
of induction therapy in relationship to recipient age or
presence or absence of treated rejection. Induction therapy
did not appear to influence the proportion of patients
experiencing rejection between discharge and 1 year after
transplant (regardless of recipient age), freedom from
coronary allograft vasculopathy (CAV), or freedom from
lymphoma.Year 1 (N = 1,393) Year 5 (N = 1,393)
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Figure 13 Maintenance immunosuppression at time of follow-
up for the same patients at each time point (Follow-up: January
2001–June 2012). AZA, azathioprine; MMF, mycophenolate
mofetil; MPA, mycophenolic acid.Maintenance
At the time of discharge from the transplant hospitalization,
the use of tacrolimus as the calcineurin inhibitor (CNI)
increased from 52% (between 2001 and 2006) to 78% (from
2007 onwards). Similarly, mycophenolate mofetil (MMF) or
mycophenolic acid (MPA) use increased from 64% to 86%,
with a concomitant drop in azathioprine use to 9% in the
most recent era. Prednisone use at the time of hospital
discharge decreased marginally to 71%. These proportions
did not vary significantly by recipient age (Figure 12).
Adjusting for multiple comparisons, there were no signifi-
cant differences in the use of CNIs or prednisone according0
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Figure 16 Kaplan-Meier survival conditional on survival to
1 year (Transplants: January 1982–June 2011).
Dipchand et al. ISHLT 16th Pediatric Heart Transplant Report 983to age group; however, the use of MMF/MPA and
azathioprine differed significantly by age group.
At a 1-year follow-up (visits from 2007 onwards), 80%
of patients received tacrolimus and 18% received cyclo-
sporine. MMF/MPA, azathioprine, and prednisone use was
77%, 13%, and 56%, respectively. Mammalian target of
rapamycin (mTOR) inhibitor (sirolimus or everolimus) use
was 10%. At 5 years after transplant, 95% of patients
remained on a CNI (tacrolimus use was 71% and cyclo-
sporine was 24%), 74% of patients remained on an anti-
metabolite (MMF/MPA use was 57% and azathioprine was
17%), mTOR inhibitor use was 20%, and steroid use was
34%. In a cohort of 1,393 patients monitored from 1 to
5 years post-transplant, the most common combination of
agents was tacrolimus and MMF/MPA (37% at 1 year and
36% at 5 years). Use of cyclosporine combined with an anti-
metabolite (MMF/MPA or azathioprine) dropped from 34%
to 18%. Monotherapy was used in 15% at 5 years after
transplant (Figure 13).
Survival
Differences remain in survival by age, diagnosis, and clinical
characteristics that impact long-term survival, now reported
out to 15 years post-transplant. Regional differences play a
role in survival as well and are examined in an exploratory
manner later in this year’s report.
Age at transplant
The youngest recipients continue to experience the longest
median survival (the time at which 50% of recipients remain
alive). Median survival was 19.7 years for infant transplant
recipients, 16.8 years for children who received transplants
between the ages of 1 and 5 years, 14.5 years for recipients
between the ages of 6 and 10 years, and 12.4 years for
adolescents (Figure 14). The infant survival curve continues
to show an increased early mortality within the first few
months but then a reduced rate of attrition.
Era of transplant
Survival curves continue to show improvement over time—
primarily in relation to reduced early post-transplant
mortality (Figure 15). For the cohort from 1982 to 1989,
median survival was 9.5 years, and in the subsequent
decade, 13.9 years. Owing to the favorable survival in the
more recent eras, the median survival is not calculable. This
era trend is evident across all recipient age groups, with the
most marked improvement within the 0- to o 1-year
recipient age category (1982–1989 median survival was
10.8 years and 1990–1999 median survival was 18.3 years).
Conditional survival
For recipients surviving the first year post-transplant, the
median conditional survival was 4 21 years for those who
received a transplant in the first year of life, 20.6 years forthose whose transplant occurred between 1 and 5 years of
age, 16.7 years for recipients between 6 and 10 years of age,
and 16.1 years for adolescents (Figure 16). These survival
outcomes are sustained and remain significantly different
between the younger age groups and the adolescents in the
most recent era (out to 9 years post-transplant).1
Pre-transplant diagnosis
Age-related differences in survival based on the pre-
transplant diagnosis were observed. For infant recipients, a
diagnosis of cardiomyopathy portended a 10 percentage
points survival advantage at 11 years after transplant
compared with congenital heart disease, mostly due to a
lower early mortality in the cardiomyopathy group.1 For the
group aged 1 to 5 years, a similar significant survival
difference was seen between cardiomyopathy and congen-
ital heart disease. In addition, patients receiving retransplant
had a lower survival than those with cardiomyopathy
(Figure 17). There was no significant survival difference
between congenital heart disease and retransplant. Similar
observations also applied to the 2 older age groups.1
Mechanical circulatory support
ECMO use as a bridge to transplantation resulted in a
markedly poorer post-transplant survival, predominantly
due to early post-transplant mortality (Figure 18). However,
survival after support with a VAD or TAH was equivalent to
survival with no MCS in the most recent era.
Immunosuppression
As noted, no difference was found in survival related to
induction usage for pediatric recipients as a group or
stratified by age1 or in survival based on type of CNI or on
the combination of immunosuppressive agents at the time of
hospital discharge.1 Interestingly, there was a difference in
survival at 11 years conditional on survival to 5 years
between patients who were receiving cyclosporine at
discharge and at 5 years and those receiving cyclosporine
at discharge and tacrolimus at 5 years (88% vs 71%, p ¼
0.0017).1 One hypothesis for this observation relates to the
reason for the switch from cyclosporine to tacrolimus
(which is not available within the Registry): if the switch
was done because of rejection or a comorbidity, this could
possibly account for the increased mortality. Prednisone use
at 1 year post-transplant remains significantly associated
with reduced 10-year survival conditional on survival to
1 year post-transplant. This was most apparent in the group
aged 1 to 5 years.1
Interaction between age, era, and geography
Last year, some regional differences for 7-year survival
were observed in survival rates by age and diagnosis; this
analysis did not include any interactions between these
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Figure 21 Relative incidence of leading causes of death
(Deaths: January 2000–June 2012). CMV, cytomegalovirus.
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Figure 20 Regional variation in 1-year mortality by recipient
age in patients with a diagnosis of congenital heart disease
(Transplants: January 2000–June 2010)
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Figure 17 Kaplan-Meier survival by diagnosis for patients
aged 1 to 5 years (Transplants: January 2000–June 2011)
0
20
40
60
80
100
0 1 2 3 4 5
Su
rv
iv
al
 (%
)
Years
* LVAD, RVAD, TAH, ECMO
All pair-wise comparisons were significant at p < 0.001 except 
No ECMO/VAD/TAH vs. VAD or TAH, no ECMO
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1-year survival.
For patients with a diagnosis of cardiomyopathy, the HR
varied according to recipient age, with the greatest HR at the
age extremes (eg, the young child or older teenager). In
addition, the risk varied according to geographic location
(Figure 19). These differences remained after adjustment in
a multivariate analysis.
For patients with a diagnosis of congenital heart disease,
there was a statistically significant interaction between0.0
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Figure 19 Regional variation in 1-year mortality by recipient
age in patients with a diagnosis of cardiomyopathy (Transplants:
January 2000–June 2010).recipient age and location for transplants performed in
Europe compared with those performed in North America
and other parts of the world (Figure 20). The HR for
mortality within 1 year was similar for Europe and North
America through approximately 9 to 10 years of age, when
the curves start to diverge. There was a steep increase in the
HR for transplants in teenaged recipients in Europe
compared with North America. However, the Registry data
do not provide us with detailed information on the types of
congenital heart disease in the individual groups. These
results vary some compared with the observations from last0
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Figure 22 Percentage of patients experiencing treated rejection
between discharge and 1-year follow-up by era (Follow-up: July
2004–June 2012).
Table 1 Cause of Death for Pediatric Heart Transplant Recipients (Deaths: January 2000–June 2012)
Cause of death
0-30 days 31 days–1 year 41–3 years 43–5 years 45–10 years 410 years
(n ¼ 290) (n ¼ 320) (n ¼ 262) (n ¼ 215) (n ¼ 379) (n ¼ 320)
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Coronary artery vasculopathy 3 (1.0) 14 (4.4) 42 (16.0) 52 (24.2) 90 (23.7) 84 (26.3)
Acute rejection 24 (8.3) 50 (15.6) 51 (19.5) 28 (13.0) 49 (12.9) 16 (5.0)
Lymphoma … 5 (1.6) 6 (2.3) 7 (3.3) 26 (6.9) 20 (6.3)
Malignancy, other … 4 (1.3) 4 (1.5) 2 (0.9) 8 (2.1) 13 (4.1)
CMV … 7 (2.2) 1 (0.4) … … …
Non-CMV infection 35 (12.1) 41 (12.8) 16 (6.1) 8 (3.7) 16 (4.2) 23 (7.2)
Graft failure 103 (35.5) 59 (18.4) 89 (34.0) 76 (35.3) 129 (34.0) 98 (30.6)
Technical 21 (7.2) 3 (0.9) 1 (0.4) 1 (0.5) 4 (1.1) 6 (1.9)
Other 22 (7.6) 25 (7.8) 23 (8.8) 16 (7.4) 26 (6.9) 18 (5.6)
Multiple organ failure 38 (13.1) 59 (18.4) 12 (4.6) 9 (4.2) 10 (2.6) 17 (5.3)
Renal failure … 7 (2.2) 1 (0.4) 1 (0.5) 2 (0.5) 9 (2.8)
Pulmonary 14 (4.8) 31 (9.7) 10 (3.8) 8 (3.7) 11 (2.9) 7 (2.2)
Cerebrovascular 30 (10.3) 15 (4.7) 6 (2.3) 7 (3.3) 8 (2.1) 9 (2.8)
CMV, cytomegalovirus.
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patients and point to the importance of further study to
understand the interplay of the factors that contribute to
post-transplant outcomes. Although this year’s analysis
focuses on 1-year survival in more depth in addition to
differences in patient and donor characteristics and center
volumes between the geographic regions, these observations
could also relate to differences in the organization of post-
transplant follow-up care and behavioral factors, including
non-adherence.
Mortality
The first year after transplant remains the period with the
highest mortality (Figure 14), although there has been
improvement over time (Figure 15). Graft failure and
technical issues accounted for 30% of deaths in this time
period, followed by multisystem organ failure (16%),
infection, including cytomegalovirus (14%), and rejection
(12%; Table 1). These causes were among the top causes of
death in all 4 age groups.1
Overall, graft failure was the most common cause of
death throughout the entire post-transplant period. Rejection
remained amongst the leading causes of death up to 10 years
after transplant, whereas deaths from infection decreased
significantly after the first year and remained low thereafter
(Figure 21). CAV as a cause of death steadily increased with
time, and beyond 3 years post-transplant, combined with
graft failure, was responsible for almost 60% of deaths
across all of the age groups.1
Risk factors for 1-year mortality
There are no surprises in the risk factor analysis for the years
2001 to 2010 for 1-year mortality (Table 2). Higher pre-
transplant clinical acuity was reflected by ECMO support
(HR, 2.65), dialysis (HR, 2.03), and mechanical ventilation
(HR, 1.35). Retransplant as a diagnosis remains a significantrisk factor (HR, 2.16), probably a reflection of worse
outcome in acute retransplants (see below). Transplant for
congenital heart disease also remains a significant risk factor
(HR, 2.04). Increasing recipient body mass index, examined
as a continuous variable, negatively affected 1-year survival
(p ¼ 0.03). Results of an expanded analysis that examined
risk factors for 1-year mortality within the different age
groups are summarized in Table 3.Risk factors for 5-, 10-, and 15-year mortality
MCS (in its different forms over the years) remains a
significant risk factor for mortality out to 15 years post-
transplant, as does a diagnosis of congenital heart disease
(Table 3). Dialysis, mechanical ventilation, and hospital-
ization at the time of transplantation also have a prolonged
impact on mortality, perhaps related to comorbidities.
Finally, retransplantation remains in the multivariate
analysis as a risk factor for mortality out to 15 years post-
transplant.Post-transplant morbidity
Functional status
Functional status data, reported in the Registry since 2005,
are predominantly from the United States, where submission
is mandatory, and assessed with the Lansky score. A score
of 100 represents full activity, 90 indicates minor restric-
tions to strenuous activity, and 80 indicates that the patient
tires more quickly but is capable of participating in physical
activity. At 1 year post-transplant, 93% of recipients have a
score of Z 80.1
Re-hospitalization rates remain high during the first year
after transplant for the cohort followed up between 2000 and
June 2012, with 49% requiring readmission: 18% for
infection, 11% for rejection, 6% for infection and rejection,
Table 2 Risk Factors for Mortality at 1 Year, N ¼ 3,516 (Pediatric Heart Transplants: January 1, 2001–December 31, 2010)
Variable No. HR (95% CI) p-value
Extracorporeal membrane oxygenation 280 2.65 (2.00–3.50) o0.0001
Retransplant 206 2.16 (1.42–3.27) 0.0003
Congenital diagnosis 1426 2.04 (1.58–2.64) o0.0001
On dialysis 123 2.03 (1.42–2.90) o0.0001
Donor cause of death ¼
Cerebrovascular/stroke vs head trauma 327 1.53 (1.11–2.11) 0.0090
Other than (head trauma, cerebrovascular/stroke, anoxia, and CNS
tumor) vs head trauma
289 1.49 (1.05–2.12) 0.0270
Anoxia vs head trauma 902 0.75 (0.58–0.97) 0.0260
Male donor/female recipient vs male donor/male recipient 913 1.44 (1.11–1.88) 0.0060
Prior sternotomy 830 1.42 (1.10–1.83) 0.0070
On ventilator 700 1.35 (1.06–1.73) 0.0170
Panel reactive antibody 4 10% 311 1.35 (1.00–1.81) 0.0500
Infection requiring intravenous drug therapy (r 2 weeks of transplant) 610 1.32 (1.03–1.69) 0.0270
Previous transfusions (borderline significant) 1265 1.25 (0.98–1.58) 0.0669
Transplant year: 2009-2010 vs. 2001-2002 (borderline significant) 779 0.75 (0.54–1.04) 0.0826
Cerebrovascular event before transplant (borderline significant) 198 0.65 (0.41–1.03) 0.0688
Donor height o0.0001
Recipient body mass index 0.0295
Ischemia time 0.0035
Recipient pre-transplant creatinine 0.0009
CI, confidence interval; CNS, central nervous system; HR, hazard ratio.
Reference group ¼ cardiomyopathy, no devices
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hospital admissions were reduced to 28%.Rejection
For this year’s analysis, rejection was separated into treated
rejection (at least 1 acute rejection episode that was treated
with an anti-rejection agent or hospitalization for rejection)
and any rejection. A significant decrease occurred in treated
rejection between July 2004 and June 2008 and July 2008
and June 2012 among all patients and in most age sub-
groups (Figure 22). This decrease also applied to any
rejection, which was reported in a greater proportion of
patients (compared with treated rejection) and was true
across all 4 age groups. As noted above, there was no
significant difference in rejection episodes based on use of
induction therapy. Tacrolimus use at the time of discharge
was associated with a significantly lower percentage of
recipients with treated rejection episodes between discharge
and 1 year post-transplant (30% reduction). Maintenance
immunosuppression of tacrolimus and MMF/MPA was
associated with significantly less treated rejection between
discharge and 1 year post-transplant compared with cyclo-
sporine and MMF/MPA.
In patients surviving past 1 year after transplant, treated
rejection within the first year after transplant was
associated with a 7 percentage points lower survival at
6 years, a greater difference than the 5% reported in
2012.2 This decrement in survival was significant in the
group aged 11 to 17 years but did not reach statistical
significance in younger children.1Coronary allograft vasculopathy
Freedom from CAV declined inexorably with time post-
transplant, with 53% of patients free of CAV 14 years after
transplant. Infant and young child (1–5 and 6–10 years)
recipients had slower progression of CAV: 31% of infants
had developed CAV by 10 years post-transplant, 29% of
1- to 5-year-olds, 36% of 6- to 10-year-olds, and 48% of
11- to 17-year-olds. After a diagnosis of CAV, graft survival
drops precipitously, regardless of recipient age, and was
approximately 50% after 5 years.1Renal dysfunction
Infant and young child (1–5 years) recipients experienced
significantly less severe renal dysfunction than adolescent
recipients—7%, 5% and 14%, respectively—at 11 years
after transplant (p ¼ 0.0008 and p ¼ 0.0005). Overall, 5%
of patients required renal replacement therapy in the form of
dialysis or renal transplant by 11 years post-transplant. As
has been shown previously, the type of CNI had no effect on
late renal function.Malignancy
Overall, 18% of patients developed a malignancy by 15
years post-transplant, the vast majority being lymphoma.
There was no effect based on induction therapy, but the
choice of CNI showed statistical significance in the younger
age groups, where the incidence of malignancy with
tacrolimus was higher.1 The nature of the Registry data
Table 3 Categoric Risk Factors for 1-Year, 10-Year, and 15-year Mortality for Pediatric Heart Recipientsa
Time post-transplant
Model
1 year by recipient age group
5-yearc 10-yearc 15-yearco1 yearb
1–5
yearsc
6–10
yearsc
11–17
yearsc
ECMO, diagnosis ¼ congenital 3.91 ... ... ... ... 3.91d ...
ECMO or VAD, diagnosis ¼ congenital ... 3.79 ... ... ... ... ...
ECMO, diagnosis ¼ not congenital 2.37 ... ... ... ... ... ...
ECMO ... ... 2.56 2.17 2.68d ... ...
Balloon pump ... ... ... ... ... 1.78 1.59
On dialysis 2.12 2.28e ... 2.47 1.67 ... ...
On ventilator 1.78 ... ... ... 1.26 1.19 1.28
Panel reactive antibody 4 10% 1.77 1.72e ... ... 1.48 1.22e ...
Prior sternotomy 1.67 ... ... ... ... ... ...
Infection requiring intravenous drug therapy
(r2 weeks of transplant)
1.64 ... ... ... 1.24 ... ...
Previous transfusion ... 2.01 ... 1.53 ... ... ...
Diagnosis
Cardiomyopathy 0.59e ... ... ... ... ... ...
Congenital ... ... 2.30e 2.17 1.62 1.95e 1.18
Congenital, no ECMO or VAD ... 1.89 ... ... ... ... ...
Congenital, no PGE or ECMO ... ... ... ... ... 1.60d ...
Congenital, age ¼ 2–17 years ... ... ... ... ... 1.27 ...
Retransplant ... ... ... 2.75 1.75 2.05 1.84
Donor cause of death ¼
Cerebrovascular/stroke vs head trauma 2.25 ... ... ... 1.28 ... ...
Other than (head trauma, cerebrovascular or
stroke, anoxia, and CNS tumor) vs head trauma
... ... ... 1.88 ... ... ...
Anoxia vs head trauma ... ... ... 0.41 ... ... ...
Donor clinical infection ... ... ... 0.68e ... ... ...
Transplant year
2003–2004 vs 2001–2002 ... ... ... 0.59b ... ... ...
2005–2006 vs 2001–2002 1.73e ... 0.27 ... ... ... ...
2007–2008 vs 2001–2002 1.85 0.50 ... 0.58e ... ... ...
2009–2010 vs 2001–2002 ... 0.49 ... ... ... ... ...
1998/1999 vs 1992/1993 ... ... ... ... ... 0.72 ...
1996/1997 vs 1992/1993 ... ... ... ... ... 0.72 ...
2000/2001 vs 1992/1993 ... ... ... ... ... 0.65 ...
1995–1996 vs 1988–1989 ... ... ... ... ... ... 0.82
Female recipient ... 1.43e ... ... ... 1.17 1.10e
Male donor/female recipient vs male donor/male recipient ... ... ... ... 1.38 ... ...
Not ABO identical ... ... ... ... 0.77 ... ...
Hospitalized at time of transplant ... ... ... ... ... 1.19 ...
Donor CMVþ/recipient CMV– ... ... ... ... ... 1.14 ...
Recipient history of malignancy ... ... ... ... ... ... 1.41e
Cerebrovascular event before transplant ... 0.30 ... ... ... ... ...
0–3 vs. 4–6 total HLA mismatches ... ... ... ... ... 0.80
2 mismatches at DR locus ... ... ... ... ... ... 0.78
CMV, Cytomegalovirus; CNS, central nervous system; ECMO, extracorporeal membrane oxygenation; HLA, human leukocyte antigen; PGE, prostaglandin E;
VAD, ventricular assist device.
eAge ¼ 1 year.
eBorderline significant.
a1 year: January 1, 2001–December 31, 2010; 5 years: January 1, 1997–December 31, 2006; 10-years: January 1992–December 2001; 15 years: January
1988–December 31, 1996 transplants.
bReference group ¼ congenital, no devices.
cReference group ¼ cardiomyopathy, no devices.
dAge ¼ 0 years.
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these differences, including the possible role of overall
intensity of immunosuppression and viral status.
Retransplantation
In 2011, 32 retransplants were reported to the Registry
(5.6% of total transplants). Retransplantation remains most
common in North America (6%) compared with the rest of
the world (2%; Figure 6). Age differences in retransplanta-
tion as an indication for transplantation were in line with
previous reports, with o 1% in infancy and rising to 9% in
the group aged 11 to 17 years. Most retransplants (72%)
occurred beyond 3 years after the primary transplant, and
when done within that interval, had similar survival to a
primary transplant. Survival for retransplants done earlier,
especially within 1 year from the primary transplant, was
much poorer. Survival after retransplantation is reduced in
all recipients aged41 year compared with cardiomyopathy
but is not significantly different from patients with
congenital heart disease (early survival curves for congenital
heart disease and retransplantation are almost superimpos-
able for older recipients).
Conclusions
The field of pediatric heart transplantation continues to
evolve. With an increasing number of patients reported to
the Registry, the trend toward larger-volume centers
continues but with different patient profiles based on region.Although indications for transplantation have remained
essentially unchanged during the last decade, immunosup-
pressant combinations continue to change with an effect on
incidence of rejection, which continues to decrease. Survival
continues to improve, and Registry data demonstrate that
some factors from very early post-transplant continue to
affect 10- and 15-year survival. Finally, exploratory
analyses continue to point toward the importance of regional
variations in practice on outcomes. The Registry continues
to be a valuable international resource documenting changes
in pediatric transplant practice.
Disclosure statement
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